Antonio Gallo is Head of the Lipid Clinic and Cardiovascular Prevention Unit and Associate Professor at Sorbonne University, Pitié-Salpêtrière Hospital in Paris, France. After completing his training in Internal Medicine at Sapienza University of Rome, he obtained a PhD in Physiology, Physiopathology and Therapeutics at Sorbonne University. His clinical activity focuses on the diagnostic and therapeutic management of genetic dyslipidaemias, with a specific interest in homozygous familial hypercholesterolaemia (HoFH) and familial chylomicronaemia syndrome. His research interests include lipid metabolism, severe forms of genetic dyslipidaemias, residual risk in primary and secondary prevention, and imaging in atherosclerosis. His current projects focus on non-invasive coronary imaging and residual risk in FH. He is involved in several randomized, placebo-controlled trials on novel lipid-lowering treatments. He has authored or co-authored more than 50 peer-reviewed publications. He is a member of European Atherosclerosis Society (EAS), New French Atherosclerosis Society (NSFA), and is involved in an EAS-endorsed consortia HoFH International Clinical Collaboration (HICC) and FH Studies Collaboration (FHSC).